The Block Firm secured two important wins in our case, Faulkner et al v. Acella Pharmaceuticals, on behalf of NP Thyroid patients. On Monday, July 10, the Court denied Acella’s attempts to limit the scope of the putative nationwide class in every respect and provided a firm roadmap for the upcoming class certification motion. Acella had asked the Court to strike Plaintiffs’ class definition and class allegation based on Plaintiffs seeking to represent a supposedly overbroad and “fail-safe” class. In a 24-page order, the Court rejected Acella’s arguments. As noted in this Law360 article, the Court went as far as to observe that certain parts of the defendants’ arguments were “a bit disingenuous,” clearing the way for class claims that potentially date back to 2010. Bloomberg also posted an article about this which you can read here . The next day, the Court rejected Acella’s attempts to hide damaging documents and ordered the company to produce information about its defective drugs. Our team at The Block Firm LLC looks forward to continuing to vigorously represent patients across the country who were injured by Acella’s fraudulent and unsafe conduct.
If you would like more information on The Block Firm’s case against Acella, please click here.
Let us help you
February 16, 2024
The Block Firm Receives Preliminary Approval of $46.5 Million Class Action Settlement
January 10, 2024
The Block Firm Investigates a Potential Class Action Against MiMedx Group, Inc.
December 11, 2023
Warning: SugarMD Advanced Glucose Support is subject to a recall due to “hidden drug ingredients” that can be harmful to health
November 30, 2023
The Block Firm Investigates Reports of Lead and Other Toxins in Children’s Snacks
November 17, 2023
AppleCare: Is Apple still charging you to cover a device they know you no longer use?
November 9, 2023
Georgia Tenants: You Have a Right to Safe Housing and Here is Why
October 24, 2023
Consumer Protection Victory: The Block Firm Successfully Protects Bank Customers from Financial Scams
August 9, 2023